Vision and mission
Vision
Leaving no one behind with immunisation
Mission
To save lives and protect people’s health by increasing equitable and sustainable use of vaccines
Mission indicators
Under-five child mortality reduction | Future deaths averted (including disaggregated for climate-sensitive diseases) | Future DALYs averted |
Reduction in zero-dose children | Children immunised | Economic benefits unlocked |
Principles
Gavi 6.0’s strategic framework includes ten principles, intended to define the Vaccine Alliance’s characteristics, its business model and its aspirations – such as being country-led and sustainable as well as community-owned and inclusive, making zero-dose and missed communities its first priority, being gender-focused, or being innovative, collaborative and accountable:
Goals and objectives
Gavi 6.0, the Alliance’s 2021–2025 strategy has four goals, each of them supporting the Alliance’s mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines. The four goals are:
1. Introduce and scale up vaccines
Gavi 6.0 will provide access to the widest, most innovative portfolio of critical life-saving vaccines ever. The Alliance will support countries vaccinate >500 million more children and adolescents, saving 8-9 million more lives, including 1.5 million through the HPV vaccine.
Gavi will prioritise three main objectives for the introduction and scaling up of vaccines:
- Strengthen countries’ prioritisation and optimisation of vaccine programmes, appropriate to their context
The Alliance will offer a wider range of vaccines in a fiscally constraint environment. It will be critical to support countries optimise their existing vaccine portfolios and prioritise and target the introduction and scale up vaccines that are most appropriate for their local context, capacity and based on evidence.
- Support countries to introduce and scale up vaccines for prevention of endemic, epidemic and pandemic diseases including beyond infancy
With the approval of the new Vaccine Investment Strategy in 2024, Gavi will provide access to vaccines against 20+ diseases, including several climate-sensitive ones such as Dengue. In particular, a new Tuberculosis vaccine is expected by the end of Gavi 6.0. It will require preparatory work to ensure readiness for rollout to reach the target age group, typically unserved by routine health services in most Gavi-eligible countries. Efficient, timely and targeted preventative campaigns will continue to be an essential part of the toolkit to prevent outbreaks and epidemics.
- Ensure equitable and timely access to mechanisms to respond to outbreaks, epidemics, and pandemics
Gavi will deepen its engagement in responding to outbreaks, epidemics, and pandemics of vaccine-preventable diseases (VPDs), whose risks are continuously rising. This includes: - Expand global vaccine stockpiles (e.g. for measles, typhoid, diphtheria, but also newer vaccines in the Gavi portfolio such as mpox and hepatitis E)
- Provide market shaping and procurement support to improve and accelerate detection and decision-making on preventative vaccination and outbreak response (through the diagnostic procurement mechanism programme)
- Support timely intervention by working with an agile coalition of partners and providing surge funding through the First Response Fund and the Day Zero Financing Facility
2. Strengthen health systems to increase equity in immunisation
Increasing equity in immunisation delivery will remain central to Gavi’s next strategy, which aims to contribute to the Immunisation Agenda 2030’s ambition to reduce the number of ‘zero-dose’ children by 50%.
To achieve this, Gavi will focus on three main objectives for strengthening health systems:
- Enable countries to extend immunisation to zero-dose children and missed communities, integrated with primary health care, including through addressing gender-related barriers and building resilient demand
Reaching zero-dose children and missed communities will remain at the heart of the Gavi’s strategy. Gavi will intensify efforts to work with other funders and health programmes to reach and integrate zero-dose investments with broader primary healthcare (PHC) programmes and ensure investments in immunisation can serve as a foundation to deliver other critical PHC services to these communities, and contribute to Universal Health Coverage..
- Ensure all children are fully immunised by maintaining and strengthening routine immunisation with vaccines required through second year of life
While Gavi 6.0 will place a strong focus on extending health systems to reach zero-dose children, it will be equally important to ensure these children, once reached, are fully immunised. The Alliance will focus on fully vaccinating children through their second year of life, particularly in missed communities. This approach is crucial for maximizing immunisation benefits, controlling measles, and successfully delivering newer vaccines like those against malaria.
- Support countries to adapt systems to routinely deliver vaccines to populations outside early childhood through targeted and catalytic interventions
The Alliance will also help countries adapt their systems to routinely deliver vaccines to populations outside early childhood (i.e. beyond second year of life) through targeted and catalytic interventions, especially guidance, advocacy, technical assistance and partnerships with others. It will offer target and catalytic support, to include guidance, advocacy, technical assistance and partnerships.
3. Improve programmatic and financial sustainability of immunisation programmes
Gavi does not just help countries expand their national immunisation programmes. It also aims to make immunisation sustainable both financially and programmatically, ensuring countries can sustain their immunisation programmes after Gavi support ends.
To support the sustainability of immunisation programmes, the Alliance will prioritise three main objectives:
- Strengthen regional, national and subnational political and social commitment to immunisation, including through increased domestic public resources
The Alliance will focus on financial sustainability by encouraging countries to invest domestic resources in co-financing Gavi-supported vaccine programmes and other investments to successfully transition out of Gavi’s support. In response to the evolving context, including a deteriorating macro-economic outlook, Gavi will enhance its eligibility, co-financing and transition model to ensure appropriate acceleration of countries’ co-financing obligations and reduce the risk of unsuccessful transitions. Learn more about Gavi 6.0 eligibility, transition and co-financing policies.
- Ensure sustainable transition through stronger capacity of eligible countries to maintain immunisation performance
In the next strategic period, Gavi will take a more deliberate approach to programmatic sustainability, helping countries maintain immunisation performance, improve efficiency, and bolster resilience. Recognizing that programmatic sustainability can be challenging as countries transition out of Gavi support, the Alliance will decouple programmatic support from vaccine support for those facing programmatic challenges and allow programmatic support post vaccine transition.
- Engage self-financing countries to maintain performance and catalyse critical vaccine introductions
Gavi will address inequities in access of vaccines in a sub-set of Former- and Never-Gavi-eligible countries and protect Gavi’s investments by mainstreaming the middle-income countries approach into a new ‘Catalytic phase’ post-transition. The support to countries will aim to catalyse new introductions and improve immunisation outcomes in a subset of Former and Never Gavi-eligible countries.
4. Ensure healthy markets for vaccines and related products
The Alliance market shaping model will remain central in 6.0 to foster a sustainable, competitive supplier base, healthy demand, and an environment that encourages innovation.
The Alliance will prioritise three main objectives to ensure healthy markets:
- Drive healthy vaccine markets for Gavi- supported and self-financing countries, including acceleration of access to new high-impact, affordable vaccines and delivery innovations
The Alliance will continue to evolve its market-shaping efforts to mitigate risks of supply disruptions and monitor healthy market dynamics, ultimately benefitting global markets beyond Gavi-eligible countries. Accelerating access to new and affordable high-impact vaccines and delivery innovations will continue to be a core part of the Alliance’s market shaping agenda in Gavi 6.0. The Secretariat will continue to coordinate closely with partners to ensure access to delivery innovations that can help increase equity and efficiency, including supporting deploy measles and rubella micro-array patches.
- Enhance regional vaccine supply security, in support of regional manufacturing expansion ambitions
Gavi 6.0 will see a substantial contribution from the Alliance towards the enhancement of regional vaccine supply security, with a focus on Africa. As parts of these efforts, Gavi is launching the African Vaccine Manufacturing Accelerator (June 2024). This considerable commitment by Gavi aligns directly with commitments at the highest levels of African country governments, to establish industrial capacities on the African continent for both pandemic response and routine immunisation.
- Develop sustainable markets for vaccines against outbreak, epidemic, and pandemic-prone diseases
The Alliance will use its comparative advantage in market-shaping to improve market conditions for vaccines against outbreak and epidemic-prone diseases. The Alliance will work to ensure the sustainability of markets for existing vaccines while continuing to work closely with CEPI and other funders to monitor progress on the pipeline of new outbreak vaccines.
Enablers
Gavi 6.0 one-pager (2026–2030)
The journey to design Gavi 6.0
- The process of designing Gavi 6.0 was led by the Gavi Board, with strong ownership of Gavi’s Chief Executive Officer (CEO) and Senior Leadership Team.
- Gavi 6.0 design was based on a highly consultative process. The Alliance’s 2026–2030 strategy design relied on extensive consultations with implementing country representatives, donor governments, core Alliance partners including the World Health Organization, UNICEF and the World Bank, as well as representatives from the vaccine industry, technical agencies, civil society and other private sector partners.
The design of Gavi 6.0 followed three main phases, each involving key touchpoints with the Gavi Board. Following the Board’s approval in June 2024, a final phase focuses on operationalising the new strategy:
The design of Gavi 6.0 concluded in June 2024. This leaves 18 months to complete the execution of the Gavi 5.0/5.1 agenda; and prepare to implement the key shifts emerging from Gavi 6.0 from day one.
Gavi 6.0 Alliance Workshop
In late February 2024, Gavi convened a broad consultation in Togo, bringing together over 120 representatives from implementing country governments, civil society organisations, and core and expanded Alliance partners.
Read the recommendations
The event marked a significant milestone in the country-centric design process for Gavi 6.0 ahead of a Gavi Board retreat in April 2024.